FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Genzyme and Isis - Billion-dollar deals

Who: Genzyme
With: Isis Pharmaceuticals
What: $1.9 billion deal

Scoop: Genzyme agreed to fork over up to $1.9 billion for rights to Isis Pharmaceutical's flagship program mipomersen, a cholesterol drug candidate. The company reportedly survived a bidding war for the drug that involved 10 companies. Mipomersen blocks a gene that opens the gate to cholesterol in the blood. It's now about to enter Phase III trials after posting some impressive data for lowering bad cholesterol.

Related Articles:
Genzyme wins Isis pact with $1.9B bid
Genzyme on buyouts: Thanks but no thanks

Is Carl Icahn out to buy Genzyme?
More good news from RNAi company Isis
Isis gains from big RNAi deal

More stories about mipomersen   Isis Pharmaceuticals   Genzyme  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 26 + 39?
To combat spam, please solve the math question above.